OSU-ERβ-12

OSU-ERβ-12 is a selective, orally active and brain-penetrant ERβ agonist with an EC50 of 78.3 nM and a Ki of 2.02 nM. OSU-ERβ-12 shows more than 200-fold selectivity for ERβ over ERα. OSU-ERβ-12 potently binds to ERβ, reducing the expression of pro-fibrotic genes mediated by TGF-β, which contributes to the reduction of liver fibrosis. OSU-ERβ-12 can be used for the study of fibrotic liver disease, non-alcoholic fatty liver disease (NAFLD), neuroinflammation[1][2][3].

Product Specifications

UNSPSC

12352005

Target

Estrogen Receptor/ERR

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Metabolic Disease

Smiles

OC(C=C1)=CC=C1C2345C678C9%10%11C%12%13%14C962C%123%15C%13%16%17C%10%14%18([C@@H](O)CCCCCC)C%117%19C%18%16%20C%1984C%17%15%205

Molecular Formula

C25H20O2

Molecular Weight

352.43

References & Citations

[1]Young GM, et al. OSU-ERβ-12: a promising pre-clinical candidate selective estrogen receptor beta agonist. Sci Rep. 2025;15 (1) :38377. Published 2025 Nov 3.|[2]Grant CV, et al. A novel targeted approach to delineate a role for estrogen receptor-β in ameliorating murine mammary tumor-associated neuroinflammation. Endocrine. 2022;75 (3) :949-958.|[3]Pankaj Kumar, et al. SAT005 Effect Of OSU-ERβ-12, A Carborane-based ERβ-selective Agonist, On Hepatic Fibrosis And NASH. Journal of the Endocrine Society, Volume 7, Issue Supplement_1, October-November 2023, bvad114.1743.